Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
29 déc. 2022 11h28 HE
|
Moore Kuehn
NEW YORK, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Nektar Therapeutics (NASDAQ:...
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
09 oct. 2019 11h00 HE
|
Glancy Prongay & Murray LLP
LOS ANGELES, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NetApp, SAExploration, Nektar Therapeutics, and Valaris and Encourages Investors to Contact the Firm
09 oct. 2019 08h00 HE
|
Bragar Eagel & Squire
NEW YORK, Oct. 09, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of NetApp, Inc. (NASDAQ: NTAP),...
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nektar Therapeutics
07 oct. 2019 11h00 HE
|
Law Offices of Howard G. Smith
BENSALEM, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors of the upcoming October 18, 2019 deadline to file a lead plaintiff motion in the class action filed...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Sarepta Therapeutics, and Canada Goose and Encourages Investors to Contact the Firm
25 sept. 2019 20h06 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics, Inc....
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
24 sept. 2019 09h02 HE
|
Schall Law
LOS ANGELES, Sept. 24, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics...
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
17 sept. 2019 08h40 HE
|
Schall Law
LOS ANGELES, Sept. 17, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics...
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
10 sept. 2019 10h20 HE
|
Schall Law
LOS ANGELES, Sept. 10, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Nektar Therapeutics, Valaris, Burford, and Textron and Encourages Investors to Contact the Firm
04 sept. 2019 12h00 HE
|
Bragar Eagel & Squire
NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Nektar Therapeutics...
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
04 sept. 2019 10h30 HE
|
Schall Law
LOS ANGELES, Sept. 04, 2019 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Nektar Therapeutics...